# Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-semaglutide-compared-with-liraglutide-and-placebo-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Patrick M. O’Neil,Andreas L. Birkenfeld,Barbara McGowan,Ofri Mosenzon,Sue D. Pedersen,Sean Wharton,Charlotte Giwercman Carson,Cecilie H. Jepsen,Maria Kabisch,John Wilding |
| Citations | 813 |
| DOI | 10.1016/s0140-6736(18)31773-2 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2885588864 |
| PMID | 30122305 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Ofri Mosenzon](https://scholariq.org/researchers/ofri-mosenzon/)
- [John Wilding](https://scholariq.org/researchers/john-wilding/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.